FDA Approves Migraine Treatment for Young Patients

AJOVY Expands to Children and Adolescents Ages 6-17

The U.S. Food and Drug Administration (FDA) has greenlit AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6 to 17 who weigh at least 45 kilograms (99 pounds). This marks a significant expansion for the calcitonin gene-related peptide (CGRP) antagonist, now offering a monthly therapeutic option for younger individuals, a group often underserved by existing treatments.

New Hope for Pediatric Migraine Sufferers

The approval positions AJOVY as the first and only CGRP antagonist indicated for both pediatric episodic migraine prevention and adult migraine prevention. This dual indication addresses a critical unmet need, providing a targeted approach to managing this debilitating neurological condition in a younger demographic.

“Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood,”

—Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva

This regulatory milestone builds upon AJOVY’s initial U.S. approval for adults in 2018. Teva Pharmaceuticals, the developer, emphasizes its commitment to advancing neurological treatments across all age groups. The drug is administered monthly, offering flexibility for in-office or at-home use, which aims to improve patient adherence and ease the burden on families.

Addressing a Widespread Pediatric Concern

Migraine affects approximately 1 in 10 children and adolescents in the United States, frequently leading to missed school days, academic difficulties, and social limitations. Historically, pediatric migraine has been underdiagnosed and undertreated, highlighting the importance of new therapeutic avenues like AJOVY.

“Pediatric migraine is a complex condition that can significantly impact a child’s daily life, from school performance to emotional well-being. Having an FDA-approved treatment like AJOVY offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.”

—Dr. Jennifer McVige, MD, MA, Pediatric Neurologist at the DENT Neurologic Institute

Understanding Migraine and AJOVY

Migraine attacks are characterized by debilitating pain, nausea, sensitivity to light and sound, and can severely impair daily functioning. In children and adolescents, this can translate to significant disability, affecting education and social engagement. AJOVY functions by targeting the CGRP pathway, a key mechanism in migraine pathology.

The medication is available as a 225 mg/1.5 mL single-dose injection. It can be administered by a healthcare professional or at home by the patient or a caregiver, with no specific starting dose required. Important safety information includes potential hypersensitivity reactions, new or worsening hypertension, and Raynaud’s phenomenon.

Teva Pharmaceuticals, headquartered in Israel with U.S. operations, is a global leader in innovative and generic medicines. The company’s dedication to improving health is reflected in its broad portfolio and ongoing research in areas such as neuroscience.

This looks like a very long string of characters representing a path or shape defined in a vector graphics format, likely SVG (Scalable Vector Graphics).It’s a series of commands and coordinates.Without rendering it, it’s hard to say exactly what it depicts, but it’s clearly a complex shape.

Here’s a breakdown of what teh characters likely mean, based on common SVG path commands:

M (Move To): Starts a new subpath. The numbers following it are the x and y coordinates. Example: M 1 1 moves the “pen” to the point (1, 1).
L (Line To): Draws a straight line from the current point to the specified x and y coordinates.
C (Cubic Bezier Curve): Draws a cubic Bezier curve. It takes six numbers: two control points and the end point.
Q (Quadratic Bezier curve): Draws a quadratic Bezier curve. It takes four numbers: one control point and the end point.
A (Elliptical Arc): Draws an elliptical arc. It takes several numbers to define the ellipse, rotation, and arc parameters.
Z (Close path): Closes the current subpath by drawing a line back to the starting point.
Numbers: Represent coordinates (x,y) or parameters for the curves and arcs. . (Decimal Point): Used to represent fractional coordinates.
- (Minus Sign): Indicates negative coordinates.

What it likely represents:

Given the complexity and the presence of curves, it’s probably a drawing of some kind. It could be:

A letter or symbol: The intricate curves suggest a stylized character.
An icon: A small graphic used in a user interface.
A part of a larger illustration: A component of a more complex image.
A geometric shape: A complex polygon or curved shape.

How to visualize it:

To see what this code actually looks* like,you need to:

Wrap it in SVG tags: You need to enclose the string within tags to make it a valid SVG document. You’ll also need to specify the width and height of the SVG canvas.
Use an SVG viewer: You can then open the SVG file in a web browser, an image editor that supports SVG (like Inkscape or Adobe Illustrator), or an online SVG viewer.

Here’s an example of how to wrap it in SVG tags:

“`xml

June 27, 2025 0 comments

preventive treatment

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

FDA Approves Migraine Treatment for Young Patients

AJOVY Expands to Children and Adolescents Ages 6-17

New Hope for Pediatric Migraine Sufferers

Addressing a Widespread Pediatric Concern

Understanding Migraine and AJOVY

France Epidemic Risk: Expect Increased Threats